Join the Fentanyl group to help and get support from people like you.
Fentanyl News (Page 2)
Opioid Rx Down, but Overdoses and Deaths Up, AMA Report Shows
WEDNESDAY, Nov. 15, 2023 – Opioid prescribing by physicians and other health professionals has decreased for the 13th consecutive year, down nearly 50 percent since 2012, while overdoses and deaths...
More Than 1 in 6 U.S. Adults, Teens Have Substance Use Disorder
TUESDAY, NOV. 14, 2023 (Healthday News) – Over 1 in 6 Americans, adults and teens alike, suffered a substance use disorder in 2022, new government data released Monday shows. In the survey, alcohol ...
One-Day Induction of XR Buprenorphine Feasible for Fentanyl Use in OUD
WEDNESDAY, Nov. 8, 2023 – For individuals with opioid use disorder (OUD) using fentanyl, a one-day induction of extended‐release buprenorphine is a feasible treatment approach, according to a study p...
FDA Medwatch Alert: Teva Initiates Voluntary Nationwide Recall of Specific Lots of Fentanyl Buccal Tablets CII Due to a Labeling Error
April 27, 2023, Parsippany, NJ – Teva Pharmaceuticals USA, has initiated a voluntary nationwide recall of specific lots of various strengths of Fentanyl Buccal Tablets CII to the Consumer Level....
FDA Medwatch Alert: Drug Safety Communication: All Opioid Pain Medicines - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use
ISSUE: The FDA is requiring several updates to the prescribing information for both immediate-release (IR) and extended release/long acting (ER/LA) opioid pain medicines. This includes stating for a...
FDA Medwatch Alert: FDA Alerts Health Care Professionals of Risks to Patients Exposed to Xylazine in Illicit Drugs
November 8, 2022 -- Health care professionals should be cautious of possible xylazine inclusion in fentanyl, heroin, and other illicit drug overdoses, as naloxone may not be able to reverse its ...
FDA Medwatch Alert: FDA Alerts Health Care Professionals of Risks to Patients Exposed to Xylazine in Illicit Drugs
November 8, 2022 -- Health care professionals should be cautious of possible xylazine inclusion in fentanyl, heroin, and other illicit drug overdoses, as naloxone may not be able to reverse its ...
FDA Medwatch Alert: Alvogen Inc. Issues Voluntary Nationwide Recall of Fentanyl Transdermal System Due to Product Mislabeling
April 19, 2019 – Alvogen, Inc. is voluntarily recalling two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level. A small number of cartons labeled 12 mcg/h...
FDA Medwatch Alert: Implanted Pumps: Safety Communication - Use Caution When Selecting Pain Medicine for Intrathecal Administration
ISSUE: The FDA is aware that patients undergoing treatment or management of pain are commonly given pain medicines in the spinal fluid (intrathecal administration) that are not FDA approved for use...
FDA Medwatch Alert: Injectable Products by SCA Pharmaceuticals: Recall - Potential Contamination
ISSUE: SCA Pharmaceuticals LLC (“SCA Pharmaceuticals”) is voluntarily recalling various lots of injectable products to the hospital level. There is a potential for the products to contain microbial co...
FDA Approves Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation
OSAKA, Japan and FLORHAM PARK, N.J. and STAMFORD, Conn., March 23, 2017 /PRNewswire/ – Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved...
Narcan (naloxone HCl) Nasal Spray 2mg Approved by U.S. Food and Drug Administration
January 25, 2017 – Dublin, Ireland – Today, the U.S. Food and Drug Administration (FDA) approved Narcan Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid ove...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications
ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...
FDA Medwatch Alert: Compounded Drugs Stored in Becton-Dickinson (BD) 3 ml and 5 ml Syringes: FDA Warning - Do Not Use
ISSUE: FDA is alerting health care professionals not to administer to patients compounded or repackaged drugs that have been stored in 3 milliliter (ml) and 5ml syringes manufactured by...
Further information
Related condition support groups
Anesthesia, Breakthrough Pain, Chronic Pain, Pain, Sedation